Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic...

Keywords

MedicineOxaliplatinFluorouracilGastroenterologyChemotherapyInternal medicinePhases of clinical researchProgressive diseasePerformance statusSurgeryColorectal cancerCancer

Affiliated Institutions

Related Publications

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy , B Paillot , Éric François +10 more

Purpose To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA). Pati...

2005 Journal of Clinical Oncology 238 citations

Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)

Atsushi Ohtsu , Yasuhiro Shimada , Kuniaki Shirao +9 more

Purpose: To compare fluorouracil (FU) alone with FU plus cisplatin (FP) and with uracil and tegafur plus mitomycin (UFTM) for patients with advanced gastric cancer in a prospect...

2002 Journal of Clinical Oncology 429 citations

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris , Malcolm J. Moore , John Sahl Andersen +11 more

PURPOSE Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a sign...

1997 Journal of Clinical Oncology 5830 citations

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

Elizabeth Poplin , Yang Feng , Jordan Berlin +9 more

Purpose Single-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clin...

2009 Journal of Clinical Oncology 423 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...

2019 The Lancet Oncology 1593 citations

Publication Info

Year: 2004
Type: article
Volume: 15
Issue: 3
Pages: 467-473
Citations: 114
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

114

OpenAlex

Cite This

APA Style

                            
                                
                                    Michel Ducreux, 
                                
                                    Emmanuel Mitry, 
                                
                                    Mahmoud Ould-Kaci
                                
                                et al.
                            
                            (2004). 
                            Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. 
                            Annals of Oncology
                            , 15
                            (3)
                            , 467-473.
                            https://doi.org/10.1093/annonc/mdh098
                        

Identifiers

DOI: 10.1093/annonc/mdh098